In particular, the widespread adoption of prostate-specific antigen (PSA) testing since the early 1990s has significantly impacted PCa incidence trends, initially leading to a sharp increase in diagnoses, particularly of early-stage, low-grade cancers [4]. This evidence concerns the gene KLK3 and cancer.